Generation_NN
of_IN
cytotoxic_JJ
T_NN
lymphocytes_NNS
against_IN
immunorecessive_JJ
epitopes_NNS
after_IN
multiple_JJ
immunizations_NNS
with_IN
adenovirus_NN
vectors_NNS
is_VBZ
dependent_JJ
on_IN
haplotype_NN
._.

Currently_RB
,_,
adenovirus_NN
-LRB-_-LRB-
Ad_NN
-RRB-_-RRB-
is_VBZ
being_VBG
considered_VBN
as_IN
a_DT
vector_NN
for_IN
the_DT
treatment_NN
of_IN
cystic_JJ
fibrosis_NN
as_RB
well_RB
as_IN
other_JJ
diseases_NNS
._.

However_RB
,_,
the_DT
cytotoxic_JJ
T_NN
lymphocyte_NN
-LRB-_-LRB-
CTL_NN
-RRB-_-RRB-
response_NN
to_TO
Ad_NN
could_MD
limit_VB
the_DT
effectiveness_NN
of_IN
such_JJ
approaches_NNS
._.

Since_IN
the_DT
CTL_NN
response_NN
to_TO
virus_NN
infection_NN
is_VBZ
often_RB
focused_VBN
on_IN
one_CD
or_CC
a_DT
few_JJ
immunodominant_JJ
epitopes_NNS
,_,
one_CD
approach_NN
to_TO
circumvent_VB
this_DT
response_NN
is_VBZ
to_TO
create_VB
vectors_NNS
that_WDT
lack_VBP
these_DT
immunodominant_JJ
epitopes_NNS
._.

The_DT
effectiveness_NN
of_IN
this_DT
approach_NN
was_VBD
tested_VBN
by_IN
immunizing_JJ
mice_NNS
with_IN
human_JJ
group_NN
C_NN
adenoviruses_NNS
._.

Three_CD
mouse_NN
strains_NNS
-LRB-_-LRB-
C57BL\/10SnJ_NN
-LCB-_-LRB-
H-2b_NN
-RCB-_-RRB-
,_,
C3HeB\/FeJ_NN
-LCB-_-LRB-
H-2k_NN
-RCB-_-RRB-
,_,
and_CC
BALB\/cByJ_NN
-LCB-_-LRB-
H-2d_NN
-RCB-_-RRB-
-RRB-_-RRB-
were_VBD
immunized_VBN
with_IN
wild-type_JJ
Ad_NN
or_CC
Ad_NN
vectors_NNS
lacking_VBG
the_DT
immunodominant_JJ
antigen_NN
-LRB-_-LRB-
s_NNS
-RRB-_-RRB-
,_,
and_CC
the_DT
CTL_NN
responses_NNS
were_VBD
measured_VBN
._.

In_IN
C57BL\/10_NN
-LRB-_-LRB-
B10_NN
-RRB-_-RRB-
mice_NNS
,_,
a_DT
single_JJ
inoculation_NN
intraperitoneally_NN
-LRB-_-LRB-
i.p._NN
-RRB-_-RRB-
led_VBD
to_TO
the_DT
recognition_NN
of_IN
an_DT
immunodominant_JJ
antigen_NN
in_IN
E1A_NN
._.

When_WRB
B10_NN
mice_NNS
were_VBD
inoculated_VBN
multiple_JJ
times_NNS
either_CC
i.p._RB
or_CC
intranasally_RB
with_IN
wild-type_JJ
Ad_NN
or_CC
an_DT
Ad_NN
vector_NN
lacking_VBG
most_JJS
of_IN
the_DT
E1_NN
region_NN
,_,
subdominant_JJ
epitopes_NNS
outside_IN
this_DT
region_NN
were_VBD
recognized_VBN
._.

In_IN
contrast_NN
,_,
C3H_NN
mice_NNS
inoculated_VBN
with_IN
wild-type_JJ
Ad_NN
recognized_VBD
an_DT
epitope_NN
mapping_NN
within_IN
E1B_NN
._.

When_WRB
inoculated_VBN
twice_RB
with_IN
Ad_NN
vectors_NNS
lacking_VBG
both_CC
E1A_NN
and_CC
E1B_NN
,_,
no_DT
immunorecessive_JJ
epitopes_NNS
were_VBD
recognized_VBN
._.

The_DT
immune_JJ
response_NN
to_TO
Ad_NN
in_IN
BALB\/c_NN
mice_NNS
was_VBD
more_RBR
complex_JJ
._.

CTLs_NNS
from_IN
BALB\/c_NN
mice_NNS
inoculated_VBN
i.p._RB
with_IN
wild-type_JJ
Ad_NN
recognized_VBD
E1B_NN
in_IN
the_DT
context_NN
of_IN
the_DT
major_JJ
histocompatibility_NN
complex_NN
-LRB-_-LRB-
MHC_NN
-RRB-_-RRB-
class_NN
I_CD
Dd_NN
allele_NN
and_CC
a_DT
region_NN
outside_IN
E1_NN
associated_VBN
with_IN
the_DT
Kd_NN
allele_NN
._.

When_WRB
BALB\/c_NN
mice_NNS
were_VBD
inoculated_VBN
with_IN
E1-deleted_JJ
Ad_NN
vectors_NNS
,_,
only_RB
the_DT
immunodominant_JJ
Kd-restricted_JJ
epitope_NN
was_VBD
recognized_VBN
,_,
and_CC
Dd-restricted_JJ
CTLs_NNS
did_VBD
not_RB
develop_VB
._.

This_DT
report_NN
indicates_VBZ
that_IN
the_DT
emergence_NN
of_IN
CTLs_NNS
against_IN
immunorecessive_JJ
epitopes_NNS
following_VBG
multiple_JJ
administrations_NNS
of_IN
Ad_NN
vectors_NNS
lacking_VBG
immunodominant_JJ
antigens_NNS
is_VBZ
dependent_JJ
on_IN
haplotype_NN
and_CC
could_MD
present_VB
an_DT
obstacle_NN
to_TO
gene_NN
therapy_NN
in_IN
an_DT
MHC-diverse_JJ
human_JJ
population_NN
._.

